LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

About this update from Lenz Therapeutics, Inc.

SAN DIEGO , May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 8, 2024 at 4:30 p.m. ET to report its first quarter 2024 financial results and provide a business update. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event. About LENZ Therapeutics LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 is a preservative-free, single-use, once-daily eye drops containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY trials as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States . LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California . For more information, visit: LENZ-Tx.com . Contacts: Dan Chevallard LENZ Therapeutics [email protected] Janhavi Mohite Stern Investor Relations, Inc. [email protected] Source: Lenz Therapeutics, Inc.

View stock analysis, news, and events for Lenz Therapeutics, Inc.